Comparative evaluation of the safety and efficacy of long-term Use of imidafenacin and solifenacin in patients with overactive bladder: A prospective, open, randomized, parallel-group trial (the LIST Study)

Advances in Urology

Volumn , Issue , 2011, Pages

  Zaitsu, Masayoshi ^a   Mikami, Koji ^a   Ishida, Noriko ^a   Takeuchi, Takumi ^a  

^a KANTO ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855173453     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2011/854697     Document Type: Article

References (32)

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., Wein A., The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Urology 2003 61 1 37 49 (Pubitemid 36151708)
2. Milsom I., Abrams P., Cardozo L., Roberts R. G., Throff J., Wein A. J., How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU International 2001 87 9 760 766 (Pubitemid 34204313)
3. Stewart W. F., Van Rooyen J. B., Cundiff G. W., Abrams P., Herzog A. R., Corey R., Hunt T. L., Wein A. J., Prevalence and burden of overactive bladder in the United States World Journal of Urology 2003 20 6 327 336 (Pubitemid 44175300)
4. Homma Y., Yamaguchi O., Hayashi K., An epidemiological survey of overactive bladder symptoms in Japan BJU International 2005 96 9 1314 1318 (Pubitemid 41743931)
5. Abrams P., Kelleher C. J., Kerr L. A., Rogers R. G., Overactive bladder significantly affects quality of life American Journal of Managed Care 2000 6 11, supplement S580 S590
6. Chapple C. R., Muscarinic receptor antagonists in the treatment of overactive bladder Urology 2000 55 5, supplement 33 46
7. Kobayashi F., Yageta Y., Segawa M., Matsuzawa S., Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors: high affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland Arzneimittel-Forschung 2007 57 2 92 100 (Pubitemid 46383949)
8. Kobayashi F., Yageta Y., Yamazaki T., Wakabayashi E., Inoue M., Segawa M., Matsuzawa S., Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats: comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task Arzneimittel-Forschung 2007 57 3 147 154 (Pubitemid 46580657)
9. Ohtake A., Ukai M., Hatanaka T., Kobayashi S., Ikeda K., Sato S., Miyata K., Sasamata M., In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats European Journal of Pharmacology 2004 492 2-3 243 250 (Pubitemid 38721378)
10. Ikeda K., Kobayashi S., Suzuki M., Miyata K., Takeuchi M., Yamada T., Honda K., M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland Naunyn-Schmiedeberg's Archives of Pharmacology 2002 366 2 97 103 (Pubitemid 34762267)
11. Kobayashi S., Ikeda K., Miyata K., Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca 2+ mobilization study in monkey cells Life Sciences 2004 74 7 843 853 (Pubitemid 37501133)
12. Madersbacher H., Halaska M., Voigt R., Alloussi S., Hfner K., A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence BJU International 1999 84 6 646 651 (Pubitemid 29457181)
13. Diokno A. C., Appell R. A., Sand P. K., Dmochowski R. R., Gburek B. M., Klimberg I. W., Kell S. H., Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clinic Proceedings 2003 78 6 687 695 (Pubitemid 36665898)
14. Homma Y., Paick J. S., Lee J. G., Kawabe K., Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial BJU International 2003 92 7 741 747 (Pubitemid 37475818)
15. Chapple C. R., Rechberger T., Al-Shukri S., Meffan P., Everaert K., Huang M., Ridder A., Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU International 2004 93 3 303 310 (Pubitemid 38253574)
16. Jnemann K. P., Halaska M., Rittstein T., Mrtz G., Schnabel F., Brnjes R., Nurkiewicz W., Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder European Urology 2005 48 3 478 482 (Pubitemid 41188408)
17. Chapple C. R., Martinez-Garcia R., Selvaggi L., Toozs-Hobson P., Warnack W., Drogendijk T., Wright D. M., Bolodeoku J., A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial European Urology 2005 48 3 464 470 (Pubitemid 41188406)
18. Anderson R. U., MacDiarmid S., Kell S., Barada J. H., Serels S., Goldberg R. P., Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder International Urogynecology Journal and Pelvic Floor Dysfunction 2006 17 5 502 511 (Pubitemid 44138258)
19. Chapple C. R., Fianu-Jonsson A., Indig M., Khullar V., Rosa J., Scarpa R. M., Mistry A., Wright D. M., Bolodeoku J., Treatment outcomes in the STAR study: a subanalysis of solifenacin 5mg and tolterodine ER 4mg European Urology 2007 52 4 1195 1203 (Pubitemid 47337035)
20. Yamaguchi O., Marui E., Kakizaki H., Itoh N., Yokota T., Okada H., Ishizuka O., Ozono S., Gotoh M., Sugiyama T., Seki N., Yoshida M., Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder BJU International 2007 100 3 579 587 (Pubitemid 47205477)
21. Choo M. S., Lee J. Z., Lee J. B., Kim Y. H., Jung H. C., Lee K. S., Kim J. C., Seo J. T., Paick J. S., Kim H. J., Na Y. G., Lee J. G., Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study International Journal of Clinical Practice 2008 62 11 1675 1683
22. Homma Y., Yamaguchi O., A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder International Journal of Urology 2009 16 5 499 506
23. Homma Y., Yamaguchi O., Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder International Journal of Urology 2008 15 11 986 991
24. Yamaguchi O., Long-term safety and tolerability of solifenacin succinate in patients with overactive bladder Japanese Pharmacology and Therapeutics 2006 34 69 86
25. Meek P. D., Evang S. D., Tadrous M., Roux-Lirange D., Triller D. M., Gumustop B., Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials Digestive Diseases and Sciences 2011 56 1 7 18
26. Oki T., Sato S., Miyata K., Yamada S., Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice British Journal of Pharmacology 2005 145 2 219 227 (Pubitemid 40756526)
27. Oki T., Maruyama S., Takagi Y., Yamamura H. I., Yamada S., Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice European Journal of Pharmacology 2006 529 13 157 163 (Pubitemid 43005298)
28. Ito Y., Kato A., Fujino Oki T. F., Okura T., Yoshida K., Nanri M., Yamada S., Muscarinic receptor binding and plasma drug concentration after the oral administration of propiverine in mice Lower Urinary Tract Symptoms 2010 2 1 43 49
29. Yamada S., Seki M., Ogoda M., Fukata A., Nakamura M., Ito Y., Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder Journal of Pharmacology and Experimental Therapeutics 2011 336 2 365 371
30. Wagg A., Compion G., Siddiqui E., Fahey A., Persistence patterns with oral antimuscarinics used for the treatment of overactive bladder in UK general practice: a retrospective analysis bya age Proceedings of the Annual Meeting of International Continence Society/International Urogynecological Association (ICS/IUGA '10) 2010 Toronto, Canada
31. Homma Y., Yoshida M., Seki N., Yokoyama O., Kakizaki H., Gotoh M., Yamanishi T., Yamaguchi O., Takeda M., Nishizawa O., Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score Urology 2006 68 2 318 323 (Pubitemid 44175525)
32. Kelleher C. J., Cardozo L. D., Khullar V., Salvatore S., A new questionnaire to assess the quality of life of urinary incontinent women British Journal of Obstetrics and Gynaecology 1997 104 12 1374 1379 (Pubitemid 27517634)